Navigation Links
Xenograft in Medical News

NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR

...old greater) as compared to docetaxel in a non-small cell lung (H460) mouse xenograft model. "The encouraging antitumor activity and unique pharmacokinetic... superior antitumor activity over docetaxel in a NSCLC mouse xenograft model and increases tumo r docetaxel exposure." Ab...

Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research

...s with both CPX-351 and CPX-1, our ongoing work in xenograft models of human cancer provides important addition...c bone marrow cells in the CCRF-CEM human leukemia xenograft model. Additional data showed median survival was...ced the efficacy observed in the LS174T colorectal xenograft model when compared to either drug used as a singl...

Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting

...demonstrated superior anti-tumor activity in tumor xenograft models in comparison to other anti-angiogenic agen..., XMT-1107 was active in a number of syngeneic and xenograft tumor models. The enhanced antiangiogenic and in ...activity seen for XMT-1107 relative to XMT-1191 in xenograft activity reported in a separate poster. Ab...

Breakthrough model for human cancer may improve development of cancer drugs; study in PNAS

...ural genetic variation akin to that seen in patients. "Historically, the xenograft models created to analyze how human cancers behave have not been accurate p...s, specifically Herceptin. This represents a big step forward in developing xenograft models that will accurately predict patient responses to agents that are in...

JCI table of contents: March 23, 2009

...lly proven, to promote tumor progression. However, Paolo Michieli and colleagues, at the University of Turin Medical School, Italy, have now developed xenograft models to examine how human lung tumors without regions of hypoxia develop and found that tumors rely on hypoxia to promote their own expansion. In...

Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors

...etaxel in colorectal (LoVo and LS174T) and non-small cell lung (H460) mouse xenograft models of human tumors. Partial regressions were observed in two of the cel...s 2.5-, 2.0-, and 1.6-fold greater than docetaxel in H460, LoVo, and LS174T xenograft models, respectively. About Nektar Nektar Therapeutics is a bi...

Also in the Feb. 10 JNCI

...eagues tested 92 human tumor samples for netrin-1 expression and examined the impact of inhibiting its expression in NSCLC cells grown in vitro and in xenograft animal models. Netrin-1 was overexpressed in 43 (47%) of the human samples tested. Inhibition of netrin-1 expression induced apoptosis in NSCLC cel...

Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting

...hese findings were supported by a separate pre-clinical study that was also reported at the ASH meeting. Using a bone marrow engrafted human leukemia xenograft model, investigators compared CPX-351 with conventional cytarabine/daunorubicin treatment. The study confirmed that CPX-351, unlike the conventional ...

Also in the Nov. 11 JNCI

...ss in Ovarian Cancer Cells Ovarian cancer cells that express lysophosphatidic acid (LPA) receptor 2 or 3 form larger and more aggressive tumors in xenograft mouse models than controls cells that do not express the receptors. LPA is a glycolipid that stimulates DNA synthesis, proliferation, survival, mig...

RTI Biologics Sees Expanded Surgeon User Base of Fresh OC Allografts

...for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries. RTI's innovations continuously raise the bar of science and safet...
Xenograft in Medical Technology

SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

DUBLIN, Calif., June 13 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced at the 13th Congress of the European Hema...

SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models

DUBLIN, Calif., April 16 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at ...

ProNAi Announces Preclinical Success for PNT2258 Therapeutic - Curative Events in Xenograft Mice for Difficult-to-Treat Non-Hodgkin's Lymphoma

LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi), today announced that its lead oncology therapeutic candidate, PNT2258, has successfully demonstrated preclinical in vivo...

Access Pharmaceuticals Announces Publication of Thiarabine Combination Data

...hern Research paper showed that thiarabine/clofarabine combinations have significantly superior efficacy to cytarabine/clofarabine combinations in the xenograft models. Thiarabine has previously been shown to have much better solid tumor efficacy than cytarabine in preclinical models. About Access: ...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

... targeting and binding to integrins that are expressed on the surface of new tumor vasculature and within the tumor compartment. In preclinical xenograft models SF1126 has demonstrated broad activity as a single agent; synergy with commonly used chemotherapy agents, targeted agents, and radiation; and h...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

...ing and binding to specific integrins that are expressed on the surface of new tumor vasculature and within the tumor compartment. In preclinical xenograft models SF1126 has demonstrated broad activity as a single agent; synergy with commonly used chemotherapy agents, targeted agents, and radiation; and h...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

... growth in acute myelogenous leukemia and lymphoma xenograft models. Efficacy of MDX-1110, an anti-Fucos... established subcutaneous tumors in a liver cancer xenograft model with no evidence of toxicity. Targeting glyp...tractive target for an antibody-drug conjugate. In xenograft models of ovarian and lung cancer, MDX-1204, a ful...

First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

...o and in vivo studies of EP-100 in ovarian cancer cell lines and ovarian xenograft models were presented in a poster presentation entitled, "Targeted Oncolyti...rison to saline or unconjugated CLIP 71 or cisplatinum in an ovarian cancer xenograft model (OVCAR-3) was studied. EP-100 regressed established OVCAR-3 xenograft...

Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

...er cells through its potentiating role in key cell survival pathways and angiogenesis. CX-4945 demonstrates potent tumor regression activity in murine xenograft models, as well as favorable PK/ADMET and safety properties in preclinical studies. "CX-4945 is a breakthrough molecule for Cylene," said Dr. Wil...

Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium

..., a novel small molecule inhibitor of Nedd8-activating enzyme, in human xenograft tumors grown in immunocompromised mice -- Lead investigator: Alliso...rmacokinetics and tumor distribution, efficacy in EGFR- and HER2-expressing xenograft models, activity in tumors harboring activated RAS or inactivated LKB1 muta...
Xenograft in Biological News

Salk researchers develop novel glioblastoma mouse model

...lls, and less than 100 and as few as 10 cells were enough to initiate a tumor when injected into immunodeficient mice," says Friedmann-Morvinski. Most xenograft models for brain tumors using tumor cell lines require at least 10,000 cells. "These findings show that our cancer model will not only allow us to...

Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc.

...linical testing. Technology developed at UCLA using lines of patented xenograft mice that can carry and grow human tumors has led to cutting-edge research ...was an initial partner in Agensys. Several patents including those for the xenograft line series (LAPC) and the prostate stem cell antigen (PSCA) tumor target d...

Finnish scientists discovered a new approach to treat virus-induced lymphomas

...in-Barr virus, despite of their wt p53 status. Moreover, the researchers show that Nutlin-3a has striking anti-tumor activity in vivo in a mouse xenograft model for the PEL. Nutlin-3a treatment resulted in a marked regression of all tumors in the treated animals in two weeks. These results demonstrate th...

A fisheye view of the deadliest breast cancer

...to breed, and a vertebrate, just like us. Being immune suppressed, the transgenic fish allowed Konstantin Stoletov and colleagues at UCSD to insert a xenograft of human MDA breast cancer cells. Being transparent, the zebrafish’s tissues gave them a window on live human cancer cells in action. The resea...

Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol

...DK activity accurately predicted which tumors would respond to Taxol in the experiments with human breast cancer cell lines and tumor tissues of human xenograft model. "This provides solid preclinical evidence that we can use toward development of a novel device that can measure CDK activity in human tissue...

Use of PET can reduce, may eliminate more strenuous drug development trials with animals

... of radiology, Bio-X Program, Stanford University School of Medicine, Stanford, Calif. * "GRP Receptor-Targeted PET of a Rat Pancreas Carcinoma xenograft in Nude Mice With a 68Ga-Labeled Bombesin(6?4) Analog" was written by Jochen Schuhmacher, Ph.D., department of diagnostic and therapeutic radiology, G...
Xenograft in Biological Technology

Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

... two ways: by reducing cancer stem cell frequency and by disrupting angiogenesis. In a series of published experiments using primary human tumors in xenograft models, OncoMed scientists assessed the effect of OMP-21M18 alone and in combination with approved chemotherapeutic agents versus chemotherapy alone o...

Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress

...ake of CPX-351 by human leukemia cells both in vitro and in vivo (mouse xenograft models).(2) They reported that CPX-351 ablated leukemic cells but permitted...h of normal bone marrow cells within 42 days of treatment in a Rag2-M mouse xenograft model. These mice remained leukemia-free for up to 70 days (saline-treated...

Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors

...utive Officer of Mersana. "These preliminary results build on our preclinical studies, which showed that XMT-1001 has greater efficacy in human tumor xenograft models than comparable doses of irinotecan, an agent with a similar mechanism of action as camptothecin and that is approved to treat patients with co...

Telik Reports Preclinical Results at AACR Annual Meeting

...rowth arrest and apoptosis in cells and leads to tumor-growth inhibition in xenograft models of human cancer. Key findings: Telik researcher...oints. More than 80% inhibition of tumor growth was seen in an HL60 xenograft model following a once daily oral dosing schedule. Drug inhibition ...

Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models

...ancreatic cancer, prostate cancer, and bladder cancer, and in several mouse xenograft cancer models. AT-406 also showed synergistic or additive effects when use...ent and has demonstrated strong single-agent antitumor activity in multiple xenograft models of human cancer, including breast cancer, pancreatic cancer, prostat...

AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting

...g of the compound, as well as in vivo pharmacokinetic experiments and mouse xenograft antitumor studies. Results AEZS-126 was identified as a potent in...hannels. During the course of in vivo pharmacokinetic experiments and mouse xenograft antitumor studies, the oral bioavailability in mice was determined to be ab...

AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting

...nd E. Guenther, the poster focuses on ADMET and safety profiling of the compound, as well as in vivo pharmacokinetic experiments and mouse xenograft antitumor studies. AEZS-126 (Poster #3706) - Entitled, "In vitro profiling of the potent and selective PI3K inhibitor, AEZS-126", I. S...

ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program

...ry anti-angiogenic activity as a consequence of the cytoskeletal disruption. The unique activity, novel structure, potent in vivo efficacy in murine xenograft models, as well as a favorable toxicity profile, potential for oral bioavailability and straight-forward cGMP manufacturing suggest that IQP-0304 mig...

Medarex Announces Allowance of Investigational New Drug Application for Company's First Antibody-Drug Conjugate, MDX-1203

...ultiple preclinical studies on several investigational antibody-drug conjugate candidates in development demonstrating enhanced anti-tumor activity in xenograft models, even with single doses as low as 0.005 micro mol/kg, when compared to the anti-cancer antibodies alone. Preclinical studies have also demonstr...

Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology

...aily dosing may be feasible with this molecule. Administration of PR-047 resulted in consistent anti-tumor responses in hematological and solid tumor xenograft models at doses below the maximum-tolerated dose. "We are pleased by the preclinical data achieved to date with PR-047, which demonstrates a ...
Other Tags
(Date:7/30/2014)... (PRWEB) July 30, 2014 Conducting ... Advanced Critical Thinking Skills and Innovative Techniques to ... Immel Resources and FDAnews**, Sept. 17-18, 2014 – ... been the #1 reason for 483 observations since ... clear: Developing a successful CAPA program has never ...
(Date:7/30/2014)... Good Neighbor Community Services announced ... episode of Innovations with Ed Begley Jr, airing ... show times TBA. , In this segment, viewers ... vision to redefine the traditional approach to serving ... Through passion, innovation, determination, excellence, and collaboration, Good ...
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 SF ... accessories at the lowest prices on the internet with ... Cables in two lengths and two colors. These lightning ... standards. , The high quality SF Cable ... connector with digital signal delivering faster charging and syncing. ...
(Date:7/30/2014)... July 30, 2014 Hamilton Facial ... of its new Carmel office on July 30th. After ... finally be moving to the state-of-the-art suite, located only ... innovative space will allow for one-on-one patient comfort, shorter ... experience. , Dr. Hamilton’s new office-suite will continue ...
(Date:7/30/2014)... ... ... ... , ... , For the study, published this week in the peer-reviewed journal Quality of Life Research , a UCLA team led by ...
Breaking Medicine News(10 mins):Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3
(Date:7/30/2014)... A group of researchers from the University of Helsinki ... experimentally to reproduce in mice morphological changes which have ... gradual modifications in the embryonic development of mice teeth, ... morphologically are very similar to those observed in the ... millions of years ago. , To modify the ...
(Date:7/30/2014)... received a pledge of $1 million from the Cornelia ... new Neurobehavioral Biometry Center. , The newly ... the Laboratory to develop a greater breadth and depth ... of accelerating the pace of research to improve human ... premier resource for the Laboratory and its external partners, ...
(Date:7/30/2014)... July 30, 2014 NexID Biometrics ... liveness detection solutions for the biometric authentication industry, ... consortium revolutionizing online authentication with standards for strong ... , "The decision to join FIDO Alliance stems ... pervasive in use. We believe the FIDO Alliance ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2NexID Biometrics Joins the FIDO Alliance 2
Other Contents